NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: sorafenib tosylate
Drug: gemcitabine hydrochloride

First Posted Date: 2004-11-09

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00095966

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: sorafenib tosylate
Other: laboratory biomarker analysis

First Posted Date: 2004-11-09

Last Posted Date: 2013-06-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00096395

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Oropharynx
Stage IV Verrucous Carcinoma of the Larynx
Stage IV Verrucous Carcinoma of the Oral Cavity
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Larynx

Interventions: Drug: ispinesib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-11-08

Last Posted Date: 2017-03-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00095628

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

Phase 2

Terminated

Conditions: Anaplastic Thyroid Cancer
Insular Thyroid Cancer
Recurrent Thyroid Cancer
Stage III Follicular Thyroid Cancer
Stage III Papillary Thyroid Cancer
Stage IV Follicular Thyroid Cancer
Stage IV Papillary Thyroid Cancer

Interventions: Drug: sorafenib tosylate
Other: laboratory biomarker analysis
Other: pharmacological study
Radiation: fludeoxyglucose F 18
Procedure: positron emission tomography
Procedure: dynamic contrast-enhanced magnetic resonance imaging

First Posted Date: 2004-11-08

Last Posted Date: 2014-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00095693

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

Phase 2

Completed

Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Low-grade Salivary Gland Carcinoma
Salivary Gland Malignant Mixed Cell Type Tumor
Low-grade Salivary Gland Mucoepidermoid Carcinoma
Salivary Gland Adenoid Cystic Carcinoma
High-grade Salivary Gland Carcinoma
Recurrent Salivary Gland Cancer
Salivary Gland Acinic Cell Tumor
Salivary Gland Adenocarcinoma

Interventions: Drug: lapatinib ditosylate
Other: laboratory biomarker analysis

First Posted Date: 2004-11-08

Last Posted Date: 2017-04-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00095563

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: lapatinib ditosylate
Other: laboratory biomarker analysis

First Posted Date: 2004-11-08

Last Posted Date: 2013-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00095667

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2004-11-05

Last Posted Date: 2019-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00095459

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Esophageal Neoplasms
Mesothelioma
Carcinoma, Small Cell

First Posted Date: 2004-10-29

Last Posted Date: 2019-12-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00094978

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: tipifarnib

First Posted Date: 2004-10-08

Last Posted Date: 2013-01-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 296

Registration Number: NCT00093418

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Drug: bortezomib
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2004-10-08

Last Posted Date: 2017-12-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00093756

Locations: 🇺🇸
Mcdonough District Hospital, Macomb, Illinois, United States
🇺🇸
Carle Foundation - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States

and more 139 locations

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer